cvot tirzepatide How the weight loss drug is also helping heart failure patients Post hoc analysis of SURPASS-CVOT

These hormonal shifts change how the body responds to GLP-1 medications and how weight loss unfolds

When paired with regular exercise and healthy meals, this method may be easier to stick with than more extreme approaches

A randomised controlled trial of 192 patients with type 2 diabetes aged 65 years found that acarbose monotherapy controlled blood-glucose levels, with no cases of hypoglycaemia reported and no clinically relevant changes in vital signs during the study [91]

H.ValtschanoffJ

Such gastrointestinal effects are a major reason for treatment discontinuation and are intrinsically linked to the mechanisms responsible for the weight loss efficacy of GLP-1RAs